Action 2137 BRII BIOSCIENCES LIMITED
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Brii Biosciences Limited

Actions

2137

KYG1645A1094

Temps Différé Hong Kong S.E.
Autres places de cotation
 10:08:09 16/07/2024 		Varia. 5j. Varia. 1 janv.
1,07 HKD +0,94 % Graphique intraday de Brii Biosciences Limited +8,08 % -53,07 %
10/06 Brii Biosciences présente des données sur les médicaments contre l'hépatite B lors d'une conférence médicale européenne MT
07/06 Brii Biosciences Limited annonce de nouvelles données provenant de deux études de phase 2 évaluant le BRII-179 CI

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024
PR
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies
PR
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
AQ
Brii Biosciences Announces Agreements To Acquire VBI Vaccines' IP Rights In BRII-179
AQ
Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies
PR
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer
PR
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 in Combination with PEG-IFN for the Treatment of Chronic Hepatitis B
AQ
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B
PR
Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results
PR
Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure
PR
Brii Biosciences Provides Latest Clinical Development and Corporate Updates
PR
Brii Biosciences Announces Entry into Definitive Agreements from Sale of its Equity Interest in Qpex Biopharma and Acquiring Exclusive Global Rights for BRII-693
PR
Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023
PR
Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders
PR
Brii Bio Publishes 2022 Environmental, Social and Governance Report
PR
Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022
PR
Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression
PR
Brii Biosciences Announces China Leadership Team Changes
AQ
Brii Biosciences Appoints Taiyin Yang to Board of Directors, Strengthening Product Quality Oversight to Support Company Momentum
PR
Brii Biosciences Provides Corporate Update and Reports 2022 Interim Results
PR
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 2137
  4. Actualités Brii Biosciences Limited
  5. Communiqués